TG Therapeutics (NASDAQ:TGTX) Issues Quarterly Earnings Results

TG Therapeutics (NASDAQ:TGTX) issued its earnings results on Monday. The biopharmaceutical company reported $0.35 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.36 by ($0.01), FiscalAI reports. The business had revenue of $259.94 million for the quarter, compared to analysts’ expectations of $245.47 million. TG Therapeutics had a return on equity of 18.52% and a net margin of 11.81%. The business’s quarterly revenue was up 60.8% on a year-over-year basis. During the same period last year, the company posted $2.43 earnings per share.

Here are the key takeaways from TG Therapeutics’ conference call:

• Positive sentiment: TG raised 2026 guidance to approximately $1 billion in global revenue, including $915 million–$920 million in U.S. BRIUMVI sales. Q3 revenue was about $260 million, up 61% year over year, and the company reported $86 million in operating income.
• Positive sentiment: BRIUMVI continued to gain commercial traction, with U.S. sales up 52% year over year and 14 consecutive quarters of sequential growth. Management cited accelerating new-patient starts, record prescriber activity, stronger hospital sales, and high persistence, while noting that it has not provided 2027 guidance.
• Positive sentiment: TG is advancing two potential BRIUMVI enhancements: a simplified single-dose IV initiation regimen, with a possible mid-2027 label update, and quarterly self-administered subcutaneous BRIUMVI, with Phase III results expected around year-end or early 2027 and a potential 2028 launch. These timelines depend on trial results and regulatory review.
• Neutral sentiment: Early azer-cel results in 26 progressive MS patients showed no dose-limiting toxicities and stable or improved disability scores in nearly 90% of evaluable patients at day 90. The findings are preliminary, and TG said longer-term follow-up is ongoing.

TG Therapeutics Trading Up 1.4%

Shares of TG Therapeutics stock opened at $64.26 on Wednesday. The company has a 50-day moving average of $56.19 and a two-hundred day moving average of $44.82. TG Therapeutics has a 12-month low of $26.76 and a 12-month high of $68.03. The company has a current ratio of 4.27, a quick ratio of 3.72 and a debt-to-equity ratio of 1.23. The stock has a market cap of $9.84 billion, a PE ratio of 97.37, a price-to-earnings-growth ratio of 2.68 and a beta of 1.89.

Insider Activity at TG Therapeutics

In other news, Director Laurence Charney sold 5,000 shares of the business’s stock in a transaction that occurred on Thursday, September 10th. The stock was sold at an average price of $54.96, for a total transaction of $274,800.00. Following the sale, the director owned 168,640 shares of the company’s stock, valued at $9,268,454.40. The trade was a 2.88% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. 8.87% of the stock is owned by company insiders.

Wall Street Analyst Weigh In

A number of research firms recently weighed in on TGTX. HC Wainwright restated a “buy” rating and issued a $78.00 price target on shares of TG Therapeutics in a research note on Tuesday, September 1st. JPMorgan Chase & Co. increased their price objective on TG Therapeutics from $65.00 to $72.00 and gave the stock an “overweight” rating in a research report on Friday, August 7th. Weiss Ratings upgraded TG Therapeutics from a “buy (b-)” rating to a “buy (b)” rating in a research report on Wednesday, November 4th. Zacks Research raised TG Therapeutics from a “hold” rating to a “strong-buy” rating in a report on Wednesday, November 4th. Finally, B. Riley Financial boosted their target price on shares of TG Therapeutics from $55.00 to $86.00 and gave the stock a “buy” rating in a research report on Monday, July 27th. One research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $63.00.

About TG Therapeutics

TG Therapeutics is a biopharmaceutical company focused on developing and commercializing treatments for B-cell diseases, including autoimmune disorders and blood cancers. Its research has centered on therapies that target B cells, a type of immune cell involved in these conditions. The company’s marketed product, BRIUMVI (ublituximab-xiiy), is an anti-CD20 monoclonal antibody approved in the United States to treat adults with relapsing forms of multiple sclerosis. TG Therapeutics also has investigated other drug candidates and combinations for immune-related and hematologic diseases.